Skip to content

Cabozantinib

Also known as Cabometyx (us)

Cancer & Oncology
Save $24,791/mo
1631× cheaper

Cabozantinib is used to treat certain types of renal cell carcinoma (RCC; a type of kidney cancer), hepatocellular carcinoma (HCC; a type of liver cancer), thyroid cancer, pancreatic neuroendocrine tumors (a type of tumor that begins in certain cells in the pancreas), and other neuroendocrine tumors…

United States
$24,806
per month
India
$15
per month
You save
$24,791
99.94% cheaper in India
50.2K US scripts/yr$1.2B potential annual savings$1.2B US spend/yr
Building 3D structure…
Drag to rotate · 3D structureC28H24FN3O5

SMILES: COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F

Compare the price
US price$24,806per month
India price$37per month
You save$24,76999.85% less

Based on 30 units per month. US $826.87 vs India $1.24 per unit.

Total over 1 periodSave $24,769$24,806$37
Is travelling to India worth it?

The savings here are large enough that a trip may still come out ahead. Adjust the numbers to your own situation — every value is an editable estimate.

Medicine savings over 6 months
$148,613
Estimated travel cost
− $2,300
Net savings after travel
$146,313

Even after travel, you could come out ahead by about $146,313.

Assumptions: medicine savings = (US − India monthly price) × months. Travel cost = flights + hotel × nights + buffer. Excludes consultation fees, visas, and other costs. For information only — not medical, legal, or travel advice.

The bigger picture

Cabozantinib is filled about 50.2K times a year under Medicare Part D. At the prices above, that works out to roughly:

Est. annual US spend
$1.2B
If sourced from India
$764K
Potential annual savings
$1.2B
100%

Rough estimate. Based on Medicare Part D prescription volume (not the entire US market) scaled by the representative monthly price — actual totals depend on dose, duration and coverage.